3SPHARMA BLOG

3S Pharma is accelerating breakthroughs in medicine as Europe’s CRO of the Year 2025. For over 25 years, our team has pioneered clinical development and bio-analytical services, turning ideas into life-changing therapies.

3S Pharma stands out today as a driving force in global medical innovation under the leadership of Dr. Simona Rizea Savu. With over 25 years of experience in clinical research, the group has built a reputation for excellence, having managed more than 1 500 registered clinical studies.

Transdermal drug delivery systems (TDDS, TDS) are innovative methods designed to administer medications through the skin, providing a non-invasive alternative to oral and injectable routes. This approach offers several therapeutic advantages, including improved patient compliance and the ability to bypass first-pass metabolism, which can enhance drug bioavailability. Transdermal drug delivery systems, (TDDS, TDS) commonly known as transdermal patches, deliver a controlled amount of medication directly into the bloodstream via the skin.

Early development clinical trials are crucial in the drug development process, primarily focusing on assessing the safety, tolerability, and initial efficacy of new medical treatments. These trials typically encompass Phase I and Phase II studies.

Comparative bioavailability and bioequivalence studies (BA/BE studies) are critical in the pharmaceutical industry, particularly for the approval of generic drugs.

Nitrosamines are a class of organic compounds characterized by the presence of a nitroso group (N=O) bonded to a nitrogen atom. They are formed primarily through the reaction of nitrous acid with secondary amines, often occurring in various foods, tobacco products, and even pharmaceuticals.